The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the EU/EEA is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC).
The European Centre for Disease Prevention and Control (ECDC) has published a report today highlighting the threat of increasing antimicrobial resistance (AMR) in Neisseria gonorrhoeae.
This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
Resistance of Salmonella and Campylobacter bacteria to commonly used antimicrobials continues to be observed frequently in humans and animals, according to a report issued today by EFSA and ECDC.
This is a summary of the fourth joint inter-agency report on integrated analysis of antimicrobial consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the European Union (JIACRA IV – 2019–2021).
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.